Combined Use of Etomidate and Propofol Reduce the Duration of Apnea vs Propofol Alone in Patients Undergoing Hysteroscopy: A Randomised Double-Blind Trial Authors: Yi Qin, Fan Ye, Teng Wang, Yijiao Chen, Xinheng Zhang, Yingyi Qin, Xinyu Gu, Liqun Yang, Ziyu Zhu, Jie Xiao Published: 2026 ABSTRACT AbstractBackgroundThe incidence of respiratory suppression remains high in outpatients receiving intravenous anesthesia for hysteroscopy, presenting a substantial risk to safety. Combined use of etomidate and propofol may reduce apnea duration compared with propofol alone.ObjectiveTo verify the co-primary hypotheses that the Etomidate-propofol combination provides non-inferior sedation efficacy and superior reduction of apnea duration compared with propofol alone.MethodsThe double-blind, parallel-group randomized trial was conducted at Renji Hospital, Shanghai, from September 2022 to December 2023. Women aged 18–65 years for elective hysteroscopies under intravenous sedation were included. The exclusion criteria included upper airway abnormalities, severe preoperative cardiac, liver, or kidney diseases, preoperative respiratory insufficiency, high reflux risk, allergy to study drugs, or serious psychological disorders or used psychotropic medications. Patients were randomized to receive either 0.2% etomidate 10mg + 1% propofol 100 mg or 1% propofol 150 mg alone, both in a total volume of 15 mL. All patients were given sufentanil (0.15 µg/kg). Co-primary outcomes were non-inferiority in sedation efficacy with an 7% margin and superiority on apnea duration.ResultsA total of 365 subjects were included with combination (n = 182) and propofol alone (n = 183). Patients in both groups were adequately sedated, and the combination was significantly non-inferior to propofol alone. Median apnea duration was significantly shorter in the combined group (73 s) than in the propofol group (116 s, difference, −43 s; P < 0.001). Fewer patients in the combined group required manual ventilation (17% vs 37% for propofol, P < 0.0001). Haemodynamic responses were similar for each approach.ConclusionThe combination of etomidate and propofol provides comparable sedative efficacy to propofol alone during hysteroscopy, while significantly shortening apnea duration induced by intravenous sedatives.Keywords: etomidate, propofol, hysteroscopy, apnea, intravenous sedation Introduction Hysteroscopy is a minimally invasive procedure used to evaluate and treat the uterine cavity and is usually performed on an outpatient basis under deep sedation or general anaesthesia.1–3 An optimal sedative regimen for hysteroscopy should be characterized by rapid onset, sufficient anaesthetic depth for the procedure, patient comfort, and a minimized profile of adverse effects. In China, sedation-based practices are employed for 75% of hysteroscopic procedures, during which nearly all anesthesiologists select propofol as their sedative.4 While propofol remains the most widely used intravenous sedative, high-dose administration is associated with vasodilation, hypotension, and respiratory compromise.5 The co-administration of propofol with other sedatives may reduce the required propofol dose and attenuate these side effects while preserving adequate sedation. Etomidate represents an alternative that produces minimal cardiovascular and respiratory depression.6 However, its use comes with the risk of muscle tremors, rigidity, and postoperative nausea and vomiting. Given that propofol mitigates these adverse effects, a combination of etomidate and propofol may represent a more favourable sedative strategy than either drug alone. Multiple studies have demonstrated that the combination of etomidate and propofol is effective for gastrointestinal endoscopy.7–10 While both hysteroscopy and gastrointestinal endoscopy are endoscopic in nature, hysteroscopic procedures are generally more time-consuming. Furthermore, cervical dilation and uterine distension are stimulating maneuvers that demand a deeper level of hypnosis. Consequently, although a propofol-etomidate combination may offer advantages over propofol alone for hysteroscopy, its efficacy and safety remain to be systematically assessed. Accordingly, we design this study to investigate the efficacy and safety of combining etomidate with propofol during hysteroscopy. We formulated these co-primary hypotheses: the combination would provide non-inferior sedation while abbreviating apnea duration. Additionally, the etomidate-propofol combination, compared with propofol alone, would be associated with a reduced need for manual ventilation, a lower incidence of hypoxaemia, and less pronounced haemodynamic depression. Methods Study Design Ethical approval for our prospective, randomised, double-blind trial (Ethical Committee Number KY2021-172-B) was provided by the Ethical Committee of Shanghai Jiaotong University School of Medicine, Renji Hospital, Shanghai, China, and registered at ClinicalTrials.gov (NCT05259787) on Feb 28th, 2022 before the first patient was enrolled. Written informed consent was obtained from the patients or their legal representative. Our trial was conducted in accordance with the Consolidated Standards of Reporting Trials (CONSORT) 2010 statement. Our study adheres to the Declaration of Helsinki. Participants We enrolled adults scheduled for hysteroscopy at Renji Hospital, Shanghai Jiaotong University School of Medicine, China, between September 2022 and December 2023. We included women aged 18–65 years who were scheduled for elective hysteroscopies under intravenous sedation. We excluded women who (1) had upper airway abnormalities that may affect airway management, which led the anesthesiologist to consider sedation unsafe; (2) were diagnosed with severe preoperative cardiac (uncontrolled blood pressure over 180/100 mmHg; New York Heart Association (NYHA) Functional Classification over class 3), liver impairment (liver enzyme levels elevated to 2 times the normal range), or kidney impairment (elevated serum creatinine, blood urea nitrogen level); (3) had preoperative respiratory insufficiency (hypoxemia (arterial PaO2 < 60 mmHg on room air), or hypercapnia (PaCO2 > 45 mmHg)); (4) were at high risk of reflux aspiration (inadequate fasting or has gastric regurgitation); (5) were allergic to propofol or etomidate; or (6) who had used sedatives, hypnotics, anti-anxiety drugs, and antidepressants in the past 3 months. First patient was enrolled on Sep 28th, 2022, and the study was finished on Dec 30th, 2023. Randomisation and Blinding Qualifying and consenting patients were randomly assigned in a 1:1 ratio without stratification to propofol alone or a combination of etomidate and propofol. Randomisation was based on computer-generated codes concealed in sequentially numbered, sealed, opaque envelopes. To conceal allocation as long as possible, an independent nurse, who was otherwise not involved in the trial, confirmed that each patient was eligible and then opened the corresponding envelopes before induction in the operating room. The nurse then prepared trial drug according to allocation result in another room. In the combined group, 10 mg (5mL) of 0.2% etomidate and 100 mg (10mL) of 1% propofol were administered in a total volume of 15 mL. In the propofol group, 150 mg (15mL) of 1% propofol was prepared in the same total volume of 15 mL. Trial drugs, all identical-looking milky fluids in syringes labelled “Trial Drug”, were then brought back to the anesthesiologist for sedation. Patients, anaesthesiologists, surgeons, and data collection personnel were all blinded to the group assignment. Study Protocol All hysteroscopies were performed by surgeons with more than 10 years of experience, who typically performed more than 30 procedures per week. Sedation was performed by attending anaesthesiologists with many years of experience. Participants fasted for at least 8h before the procedure, which was conducted with electrocardiogram (ECG), percutaneous arterial oxygen saturation (SpO2), non-invasive blood pressure (NBP) monitoring. Nasal oxygen (5 L/min) was provided. Sufentanil 0.15 µg/kg was given intravenously and was followed by 0.2 mL/kg of the trial drug, which was infused intravenously for 10 seconds during Anesthesia induction. An additional 0.1 mL/kg of the trial drug was added if the patient showed signs of insufficient anaesthesia, such as movement or grimacing. Mask-assisted ventilation was used when SpO2 was <90%. Vasopressors (including Ephedrine, Noradrenaline, Epinephrine, etc.), were used to target a systolic blood pressure within 20% of the baseline. Microstream capnography was used to quantify ventilation and apnea episodes,11,12 which could supply a real-time measurements of partial pressure of end-tidal carbon dioxide (PetCO2), SpO2, pulse rate (PR), and respiratory rate (RR) with high accuracy. Integrated pulmonary index (IPI) is a mathematically-derived index based on these parameters, which can provide clinicians with an integrated reference of respiratory status.13 By assigning clinical responses to specific IPI scores, it simplifies the interpretation of continuous oxygenation and ventilation monitoring. It uses a numerical scale from 1 to 10 to represent different respiratory states, with 1 indicating severe respiratory dysfunction and 10 indicating optimal respiratory status. Based on IPI thresholds 3–6, it had been proven to provide a high levels of sensitivity and specificity (ranging from 0.96 to 0.74).14 When hysteroscopy was completed, the patient was transferred to the post-anaesthesia care unit (PACU) for 1 h of observation. Arterial blood was sampled for gas analysis in PACU by a nurse blinded to the treatment group, according to hospital routine; treatment-blinded nurses also identified complications and evaluated nausea and vomiting. Tropisetron or metoclopramide was given when necessary to treat nausea and vomiting. Patients were discharged from the PACU when their modified Aldrete scores exceeded 9. Hypoxaemia was defined as SpO2 < 95% while severe hypoxaemia was defined as SpO2 of ≤90% or a respiratory rate of <8 breaths per minute for at least a minute. Outcome Assessment The co-primary outcomes were adequacy of anaesthesia for efficacy as non-inferiority design and apnea duration as superiority design. Anaesthesia was considered effective when the sedation was sufficiently deep for hysteroscopy, as defined by a Modified Observer’s Assessment of Alertness and Sedation (MOAA/S) score between 0 and 2. The MOAA/S score was assessed on a 6-point scale: level 0, no response to painful trapezius squeeze; level 1, responsive only after painful trapezius squeeze; level 2, responsive only after mild prodding or shaking; level 3, responsive only after the name is called loudly and/or repeatedly; level 4, lethargic response to a name spoken in a normal tone; and level 5, responds readily to a name spoken in a normal tone.15 The MOAA/S score was assessed before induction as baseline; at 1, 2, 3, 4, 5, and 10 min after induction; and at 5-min intervals from 15 min after induction until the end of surgery. Apnea duration was defined as the interval between the disappearance of spontaneous respiration and spontaneous recovery, which manifested as the disappearance and recovery of the end-tidal carbon dioxide (EtCO2) waveform recorded by Microstream capnography. Secondary outcomes included the incidence of severe hypoxaemia (SpO2 < 90%), unacceptable body movement during the procedure, total dose of the study drugs, time to recovery, haemodynamic changes during anaesthesia, oxygenation (arterial oxygen partial pressure [PaO2] and arterial oxygen partial pressure [PaCO2]) in the PACU. Adverse events such as bradycardia, hypotension, laryngospasm, and postoperative nausea and vomiting (PONV) were also recorded. Statistical Analysis and Sample-Size Estimation Sample size was estimated based on two co-primary endpoints as superiority for safety (apnea duration) and non-inferiority for efficacy (adequacy of anaesthesia) respectively. In our pilot study (N=20), apnea duration in patients who were given the combined regimen was 85 ± 28s in comparison with 178 ± 52s in patients given propofol alone. With α = 0.025 and β = 0.2, the sample size was also estimated to be 6 patients per group. Meanwhile, sedation was effective in 95% of patients given propofol, similar to the efficacy in patients given a combination of etomidate and propofol. Since efficacy was near 100%, with a non-inferiority margin of −7%, α = 0.025 (one-sided), and β = 0.2, the required sample size was estimated to be 153 patients per group by likelihood score analysis. Considering a potential 20% loss, the final sample size (366 patients) was determined by the efficacy endpoint, which required the larger sample. The adequacy of anaesthesia was assessed in the intention-to-treat population. The success of etomidate combined with propofol and propofol alone was estimated, and the corresponding 95% confidence intervals (CIs) were calculated using the Newcombe–Wilson method.16 Apnea duration was assessed with a t-test. We specified that the combination of etomidate and propofol would only be considered superior if both co-primary outcomes were statistically significant and therefore used an alpha threshold of 0.05 for each without adjustment. The incidence difference and Clopper–Pearson 95% CI were calculated for the secondary outcomes, hypoxaemia and severe hypoxaemia. We described the trend of haemodynamic outcome changes and performed an analysis using a mixed-effects model, incorporating the interaction between treatment and time into the model. Other outcomes were compared with t, Wilcoxon rank-sum, or chi-squared tests. Continuous variables are presented as means (standard deviation) or medians (interquartile range), and categorical variables as frequency (%). We used t, Wilcoxon rank-sum, or chi-squared tests to compare the baseline characteristics of patients assigned to each treatment. R (version 4.0.3, Vienna, Austria) and SAS (version 9.4, SAS Institute Inc., Cary, North Carolina, USA) were used for all analyses. Statistical significance was set at a two-tailed P < 0.05. Results We screened 400 patients, of whom 365 were enrolled and randomised. A total of 183 patients were randomised to propofol group, and 182 to combination of etomidate and propofol group (Figure 1). First patient was enrolled on Sep 28th, 2022, and the study was finished on Dec 30th, 2023. Patient Flow Diagram. Patients’ baseline characteristics are presented in Table 1. The average age was 39 in propofol group and 37 in combined group. BMI was 22 in both groups. Most patients were diagnosed with endometrial polyps, endometrial atypical hyperplasia or intrauterine lesions. Common comorbidities were hypertension and diabetes. 16 in propofol group and 24 in combined group had allergic history. Over 90% patients had ASA level of 1~2, and the majority were assessed with Mallampati scores below 4. Table 1Baseline CharacteristicsPropofol(n = 183)Etomidate & Propofol(n = 182)P valueAge, Median (IQR)39 (33,48)37 (31,46)0.034Sex1.000 Male0 (0)0 (0) Female183 (100)182 (100)BMI, Median (IQR)22 (20, 24)22 (20, 24)0.906Diagnosis, n (%)0.706 Intrauterine lesions30 (16)33 (18) Endometrial polyps78 (42.86)67 (37) Endometrial atypical hyperplasia32 (18)35 (19) Female infertility22 (12)23 (13) Postmenopausal bleeding4 (2)2 (1) Menoxenia2 (1.10)4 (2) Leiomyoma5 (3)10 (6) Others9 (5)6 (3)Comorbidity, n (%)49 (27)44 (24)0.569 Hypertension21 (11)20 (11)0.883 Diabetes3 (2)5 (3)0.715 CHD1 (1)0 (0)1.000 Arrhythmia10 (5)6 (3)0.312 Asthma1 (0.55)0 (0)1.000 CVD2 (1)0 (0)0.499 Others20 (11)20 (11)0.985Allergy16 (9)24 (13)0.174Basic vital sign HR, Median (IQR)76 (68, 85)74 (65, 83)0.128 SBP, Median (IQR)133 (12, 144)130 (121, 140)0.322 DBP, Median (IQR)79 (72, 89)80 (71, 88)0.989 RR, Median (IQR)17 (15, 19)17 (15, 20)0.594ASA n (%)0.612 1141 (77)147 (81) 237 (20)32 (18) 35 (3)3 (2)Mallampati, n (%)0.163 1141 (77)129 (72) 227 (15)30 (17) 312 (7)21 (12) 42 (1)0 (0)Notes: Data are n(%) or median and interquartile range (IQR).Abbreviations: BMI, Body mass index; CHD, coronary heart disease; CVD, Cardiovascular Disease; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; RR, respiratory rate; ASA, American Society of Anaesthesiologists. Baseline Characteristics Notes: Data are n(%) or median and interquartile range (IQR). Abbreviations: BMI, Body mass index; CHD, coronary heart disease; CVD, Cardiovascular Disease; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; RR, respiratory rate; ASA, American Society of Anaesthesiologists. More than half patients underwent endometrial polypectomy (Table 2). The median duration of anesthesia was 8 minutes, while the median duration of surgery was 7 minutes. Both groups were given similar volumes of the trial drug, averaging approximately 16 mL. All patients stayed in PACU for 60 minutes, as per hospital routine. Table 2Surgical and Anaesthesia Related DataPropofol(n = 183)Etomidate & Propofol(n = 182)P valueSurgery, n (%)Endometrial polypectomy115 (63)101 (55)0.153Hysteroscopic lysis of adhesions23 (13)22 (12)0.889Endometrial biopsy56 (31)55 (30)0.937Submucosal myomectomy9 (5)12 (7)0.492Hydrotubation33 (18)33 (18)0.980Hysteroscopy examination2 (1)2 (1)1.000Others6 (3)7 (4)0.770Anaesthesia duration, Median (IQR)8 (6,10)8 (6,11)0.425Surgery duration, Median (IQR)7 (4,9)7 (5,9)0.389Total dose of trial drugs16 (13,19)16 (13,19)0.649PACU duration, Median (IQR)60 (60,60)60 (60,60)0.159Notes: Data are n(%) or median and interquartile range (IQR).Abbreviation: PACU, Postanaesthesia care unit. Surgical and Anaesthesia Related Data Notes: Data are n(%) or median and interquartile range (IQR). Abbreviation: PACU, Postanaesthesia care unit. The two groups showed no significant differences in sedation efficacy (defined by MOAA/S scores of 0–2) at any assessment point (Supplementary table 1). All patients in both groups were successfully anaesthetised; the 95% CI for the difference (−0.021, 0.021) was considerably smaller than the non-inferiority threshold of −0.07. The MOAA/S scores were low and adequate in all patients in both groups, as shown in Figure 2A. A total of 167 apnea events were observed in 182 patients in propofol group (incidence, 91%; 95% CI: 86–95%), while 142 apnea events were observed in 183 patients in combined group (incidence, 78%; 95% CI: 71–84%), with a significant difference (−13% [95% CI: −21%, −6%], P < 0.001; Figure 2B). Apnea duration was significantly shorter in the combined group (73 s; 95% CI: 65–81 s) than in propofol group (116 s; 95% CI: 105–126 s) (mean difference: −43 s; 95% CI: −56 to −29 s; P < 0.001; Figure 2C). The apnea onset time after sedation induction was shorter in propofol group (34 s; 95% CI: 32–35 s) than in those given combined group (37 s; 95% CI: 35–39 s; P = 0.009; Figure 2D). Effective rate of anaesthesia, apnoea events and apnoea time. (A) Overall MOAA/S score. (B) Incidence rate of apnoea events. Etomidate and Propofol, Event=142, Percent=78%, 95% CI:71%~84%; Propofol alone, Event=167, Percent=91%, 95% CI:86%~95%; Ratio difference and 95% CI: −13%(−21%~-6%), P<0.001. (C) Apnoea duration. Etomidate and Propofol, mean and 95% CI: 72(65~81)s; Propofol alone, mean 95% CI: 116(105~126)s; Mean difference and 95% CI: −42.6(−56~-29)s, P<0.001. (D) Onset time of apnoea from induction. Etomidate and Propofol, mean and 95% CI: 37(35~39) s; Propofol alone, mean 95% CI: 33.5(32~35) s; Mean difference and 95% CI: 4 (1~6) s, P=0.009. The incidence of hypoxemia was significantly lower in the combined group compared to the propofol group (47% vs 59%; P = 0.031), as was the incidence of severe hypoxaemia (14% vs 34%; P < 0.001, Table 3). Significantly fewer patients in the combined group required high-flow oxygen than those randomized to propofol alone (47% vs 58%; P = 0.0342), and fewer required mask ventilation (17% for etomidate and propofol vs 37% for propofol alone; P < 0.001) (Table 4). No patients in either group required laryngeal mask ventilation or tracheal intubation. Table 3Hypoxaemia Related DataPropofol (n=183)Etomidate & Propofol (n=182)P valueEventRate or Mean (95% CI)EventRate or Mean (95% CI)Hypoxaemia*10759% (51%~66%)8647% (40%~55%)0.031 -Onset time from induction (s)80 (72~88)77 (70~85)0.651Severe Hypoxaemia#6334% (28%~42%)2614% (10%~20%)<0.001 -Onset time from induction (s)91 (79~103)78 (65~91)0.225Notes: *Hypoxaemia was defined as SpO2<95%. #Severe Hypoxaemia was defined as SpO2 of ≤90% or a respiratory rate of <8 breaths per minute for at least a minute. Data are n or incidence rate with corresponding 95% confidence interval (95% CI). Hypoxaemia Related Data Notes: *Hypoxaemia was defined as SpO2<95%. #Severe Hypoxaemia was defined as SpO2 of ≤90% or a respiratory rate of <8 breaths per minute for at least a minute. Data are n or incidence rate with corresponding 95% confidence interval (95% CI). Table 4Hypoxaemia Rescue methodsPropofol(n = 183)Etomidate &Propofol(n = 182)P valueAll individuals, n (%) Increasing oxygen flow Yes104 (58)83 (47)0.034 No75 (42)94 (53) Mask ventilation Yes66 (37)30 (17)<0.0001 No113 (63)147 (83) Laryngeal mask ventilation Yes0 (0)0 (0)1.000 No178 (100)177 (100) Tracheal intubation Yes0 (0)0 (0)1.000 No177 (100)176 (100)Notes: Data are represented as n(%). Hypoxaemia Rescue methods Notes: Data are represented as n(%). Patients who received the combination of etomidate and propofol exhibited more stable hemodynamic changes (as indicated by systolic and diastolic blood pressure), along with higher pulse oxygen saturation, respiratory rate, and integrated pulmonary index. (Figure 3). Haemodynamic variables. (A) Heart rate (per minute). P for treatment=0.7405, P for interaction of treatment and time=0.4504. (B) Systolic blood pressure (mmHg). P for treatment=0.0454, P for interaction of treatment and time=0.0023. (C) Diastolic blood pressure(mmHg). P for treatment=0.0301, P for interaction of treatment and time=0.0807. (D) Pulsatile oxygen saturation (%). P for treatment=0.0123, P for interaction of treatment and time=0.0036. (E) End tidal carbon dioxide (mmHg). P for treatment< 0.0001, P for interaction of treatment and time< 0.0001. (F) Respiratory rate (per minute). P for treatment=0.0003, P for interaction of treatment and time< 0.0001. (G) Integrated pulmonary index. P for treatment< 0.0001, P for interaction of treatment and time=0.0003. 6 patients in group propofol alone were given vasopressor (ephedrine 6mg) to improve the hypotension, while only one in group combined etomidate and propofol needed. Safety Assessment Outcomes As for adverse events (Table 5), 16 patients in propofol group and 12 in the combined group experienced intraoperative hypotension, with no statistically significant difference. 4 patients (2%) in the combined group experienced transient, mild, and self-limiting myoclonus during induction. Other side effects were rare and comparably distributed between the treatment groups. No serious adverse events were observed. Table 5Adverse Events PerioperativelyPropofol(n = 183)Etomidate & Propofol(n = 182)P valueAdverse events, n (%)Intraoperative hypotension16 (9%)12 (7%)0.440Postoperative complications2 (1%)5 (3%)0.441PONV1 (1%)0 (0%)1.000Fluid overload1 (1%)1 (1%)1.000Myoclonus04 (2%)0.061Notes: Data are represented as n(%).Abbreviation: PONV, postoperative nausea and vomiting. Adverse Events Perioperatively Notes: Data are represented as n(%). Abbreviation: PONV, postoperative nausea and vomiting. Discussion This single-center randomised study discovered that the combination of etomidate and propofol reduced the duration of apnea compared with propofol alone in patients undergoing hysteroscopy, with a mean difference of −43 seconds, 95% CI: −56 to −29 s (p < 0.001), thereby supporting our primary superiority hypothesis for the safety endpoint. For the primary efficacy endpoint, the combination regimen achieved non-inferior adequacy of anaesthesia compared with propofol alone, confirming that the reduced propofol dose did not compromise sedative effectiveness. Regarding secondary outcomes, the combination group exhibited significantly lower incidences of hypoxaemia (SpO2 < 95%, p = 0.031) and severe hypoxaemia (SpO2 ≤ 90% or respiratory rate < 8/min for at least one minute, p < 0.001), as well as fewer rescue interventions including increased oxygen flow (p = 0.034) and mask ventilation (p < 0.001). The improved respiratory safety profile is mechanistically attributable to the reduced propofol requirement facilitated by etomidate co-administration, as propofol-induced cardiorespiratory depression is dose-dependent. Etomidate is a well-established intravenous anesthetic characterized by rapid onset and hemodynamic stability with minimal cardiorespiratory depression. Combining etomidate with propofol in procedures have been proven to improve the safety profile, reduce the total propofol requirement, and promote faster recovery in some gastrointestinal endoscopy studies. Collectively, our findings provide a new evidence that the combined regimen offers an optimal balance between safety and efficacy for sedation in hysteroscopic procedures. The reported incidence of SpO2 < 95% with propofol monotherapy ranges from 3% to 51%. In the present study, the overall incidence of hypoxemia was 11%. The etomidate-propofol group demonstrated significantly lower rates of hypoxemia (SpO2 < 95%, p = 0.031) and severe hypoxemia (SpO2 < 90%, p < 0.001) compared to the propofol group. Furthermore, this group required fewer interventions, including increased oxygen flow (p = 0.034) and mask ventilation (p < 0.0001). These findings are attributable to the inclusion of etomidate and the associated reduction in propofol dosage, aligning with results from prior studies.17,18 Etomidate propofol co-administration is not new and has been explored in several gastrointestinal endoscopy studies.19 Outcomes vary depending on the combination ratio, with a 1:1 volume ratio of propofol (10 mg /1 mL) and etomidate (2 mg /1 mL) being the most frequently reported.6–8 A 1:2 ratio (10 mg /1mL propofol to 1 mg/ 0.5mL etomidate) has been associated with reduced incidence of nausea, vomiting, muscle spasms, and involuntary movements during gastroscopy.19 While higher doses of etomidate may improve hemodynamic stability, they can also increase the risk of myoclonus. In our study, we used a 1:2 volume ratio and observed no cases of severe hypotension, likely due to the relatively young age of the study population (mean age 38 years). There was no difference in other adverse reactions, such as PONV which has a high incidence in female population.18 A limitation of etomidate is its propensity to induce myoclonus, which may also have a potential risk for functional unblinding. Although myoclonic movements are typically self-limiting and of short duration, they can nonetheless interfere with and prolong the procedure. In our trial, the incidence of myoclonus in the combination group was only 2%, which was not statistically significant. Meanwhile, the potential for functional unblinding due to etomidate-associated myoclonus was minimized by double-blind design incorporated two independent layers of blinding: the administering anesthesiologist and, critically, the outcome assessor who recorded all respiratory parameters were both blinded to group allocation. Since the outcome assessor was not present during drug induction and had no interaction with the patient at that time, the potential for bias in outcome measurement was minimized. In our study, apnea was designated as the primary endpoint rather than hypoxemia, given that patients may present with apnea in the absence of a corresponding decline in oxygen saturation. A major methodological strength of this investigation is the application of microstream capnography for respiratory waveform monitoring, which permits accurate and early detection of apneic events. This approach is of particular importance in patients with diminished oxygen reserves or heightened susceptibility to hypoxia, as the early recognition of apnea facilitates timely intervention prior to the onset of oxygen desaturation. Limitations Several limitations of our study should be acknowledged. First, this was a single-center investigation, which, while standardizing procedure complexity, inevitably limits the generalizability of our findings. Second, we did not perform electroencephalographic monitoring (eg, bispectral index) to objectively assess sedation depth. This modality is not part of the standard protocol for this procedure in our institution due to cost implications. Consequently, sedation depth was indirectly inferred using the MOAA/S scale and hemodynamic parameters (heart rate, blood pressure, and oxygen saturation), per institutional routine. Third, recovery time and recovery status were not formally recorded. Of note, however, all participants underwent 60 minutes of postoperative monitoring in the PACU, and none required extended observation beyond this period. Conclusion In conclusion, the combination of etomidate and propofol, administered at a 1:2 volume ratio, demonstrated superior safety in reducing apnea duration and hypoxaemia compared with propofol alone in patients undergoing hysteroscopy, while maintaining non-inferior anaesthetic efficacy. The improved respiratory safety profile, coupled with a low incidence of myoclonus and no increase in other adverse events, suggests that this combined regimen represents a favorable sedative strategy for hysteroscopic procedures. However, given the limitations of this single-center study, further large-scale, multicenter trials are needed to validate these findings in broader and higher-risk patient populations. Acknowledgment This paper has been uploaded to ResearchSquare as a preprint: https://www.researchsquare.com/article/rs-9563995/v1. Funding Statement This study was supported by the National Natural Science Foundation of China (grants 32170995, 82001227, and 82201369), grants from Shanghai Engineering Research Center of Peri-operative Organ Support and Function Preservation (No. 20DZ2254200) and the Fundamental Research Funds for the Central Universities under Grant (No.24X010202059), Clinical Research and Cultivation fund of Renji Hospital (No. RJPY-LX-012). Scientific Research Project of the Chinese Society of Cardiothoracic and Vascular Anesthesia (No. CSCTVA0102032202601). Trial Registration ClinicalTrials.gov identifier: NCT05259787, first published on Feb 28th, 2022. First patient was enrolled on Sep 28th, 2022, and the study was finished on Dec 30th, 2023. Data Sharing Statement The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials. Author Contributions Study design and conception: Yi Qin, Fan Ye, Teng Wang, Liqun Yang, Ziyu Zhu, Xiao Jie Data acquisition, analysis, and interpretation: Yi Qin, Fan Ye, Yingyi Qin, Ziyu Zhu, Xiao Jie All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The authors declare no competing interests in this work. References Associated Data Data Availability Statement The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.